Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 06, 2023 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology
October 20, 2022 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced...
Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer
September 29, 2022 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
Recludix Pharma Announces the Appointment of Seasoned Biotech Leader Athena Countouriotis, M.D., as the Chairperson of the Board of Directors
September 13, 2022 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
Recludix Pharma Announces Scientific Advisory Board
January 06, 2022 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...
Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO
November 15, 2021 08:00 ET
|
Recludix Pharma, Inc.
Three SH2 domain inhibitor programs targeting STAT3, STAT6 and an undisclosed non-STAT target are underwayNancy Whiting, Pharm.D. -- an industry veteran and one of Fierce Pharma’s Fiercest Women in...